Table 1. . Summary of patient demographics.

Demographic		Number
Age, median (months)		67 ± 14.3
Duration of follow-up, median (months)		7 (1–55)
Gender:	Male	38 (74.5%)
	Female	13 (25.5%)
Performance status:	0	30 (58.8%)
	1	19 (37.2%)
	2	2 (4.0%)
Cancer type:	Cutaneous melanoma	46 (90.2%)
	Ocular melanoma	5 (9.8%)
Primary cancer resected prior to therapy:	Yes	43 (84.3%)
	No	8 (15.7%)
Number of systemic treatments prior to therapy:	0	44 (86.3%)
	1	7 (13.7%)
BRAF mutation status:	Wild-type	36 (70.6%)
	Positive	6 (11.8%)
	Unknown	9 (17.6%)
Nature of prior treatment:	Immunotherapy	3
	Chemotherapy	4
Type of immunotherapy:	Ipilimumab	16 (31.4%)
	Nivolumab	2 (3.9%)
	Pembrolizumab	33 (64.7%)
Mean number of cycles of immunotherapy:	Ipilimumab	3.5 (2–4)
	Nivolumab	3.5 (3–4)
	Pembrolizumab	14.7 (1–50)
Presence of hypophysitis:	Yes	6 (11.7%)
	No	45 (88.3%)